SCHEMBL3017685

SCHEMBL3017685

Cn1cnc([C@]2(OCC3CC3)CC[C@@](C(=O)O)(c3ccccc3)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.37
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
OPRM1 P35372 2/20 0.34
ALOX15 P16050 1/20 0.34
SLC22A1 O15245 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
KCNH2 Q12809 1/20 0.34
LPAR1 Q92633 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KMT2A Q03164 4/20 0.33
TET3 O43151 1/20 0.33
FBXL19 Q6PCT2 1/20 0.33
CXXC5 Q7LFL8 1/20 0.33
TET1 Q8NFU7 1/20 0.33
KDM2B Q8NHM5 1/20 0.33
CXXC4 Q9H2H0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017687 1.00 AKR1C1 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3017688 1.00 AKR1C1 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3023553 0.85 AKR1C1 (0.38) AKR1C1CYP2C19CYP1A2OPRM1LPAR1
SCHEMBL3029078 0.81 JAK2 (0.37) OPRM1OPRD1KMT2AMEN1
SCHEMBL3015134 0.79 AKR1C1 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3015132 0.79 AKR1C1 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3015136 0.79 AKR1C1 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3023037 0.77 CYP2C19 (0.37) AKR1C1CYP2C19CYP1A2OPRM1ALOX15
SCHEMBL3007935 0.76 PTGIR (0.36) AKR1C1CYP2C19CYP1A2KMT2A
SCHEMBL3007929 0.76 PTGIR (0.36) AKR1C1CYP2C19CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164825-B1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM SANOFI SA (FR) 2014-04-30 EP disclosed
US-8076324-B2 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2011-12-13 US disclosed
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them ATP2A1, ATP2A2, RYR2 AKR1C1 338/4885CYP2C19 639/4885CYP1A2 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.